AR and prostate cancer: We discovered that the ubiquitin-mediated proteolysis pathway and proteasome activity are suppressed in enzalutamide and abiraterone-resistant prostate cancer cells, and play a critical role in the degradation of the AR and its variants, particularly AR-V7.